Welcome to our dedicated page for Palatin Tech SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech disclosure shouldn’t feel like decoding a lab notebook, yet Palatin Technologies’ SEC documents are packed with clinical data tables, cash-runway projections and detailed licensing terms. If you’re searching for Palatin Technologies SEC filings explained simply, or wondering how the latest 8-K material event affects trial timelines, you’re in the right place.
Stock Titan’s AI quickly dissects every filing type—whether it’s a Palatin Technologies quarterly earnings report 10-Q filing outlining R&D spend, an 8-K announcing Phase 2 results, or a shelf registration that could dilute shareholders. Our algorithm highlights the sections that matter: safety signals, FDA correspondence, partnership revenue and dilution triggers. You can also track Palatin Technologies Form 4 insider transactions real-time, receive instant summaries of executive stock moves and view a plain-language breakdown of the Palatin Technologies annual report 10-K simplified.
Use this page to:
- Monitor Palatin Technologies executive stock transactions Form 4 before key clinical readouts
- Compare quarter-over-quarter trial expenses with our Palatin Technologies earnings report filing analysis
- Dive into the definitive proxy for Palatin Technologies proxy statement executive compensation details
- See every Palatin Technologies insider trading Form 4 transactions alert the moment it hits EDGAR
- Get concise explanations of Palatin Technologies 8-K material events explained by AI
Whether you’re assessing cash burn, partnership economics or potential dilution, our platform turns hundreds of pages into actionable insights—helping you understand understanding Palatin Technologies SEC documents with AI in minutes, not hours.
On June 30, 2025, MediaAlpha, Inc. (NYSE: MAX) filed a Form 8-K announcing technology-leadership changes and related compensation matters.
Item 5.02 – Executive transition. Chief Technology Officer Eugene Nonko resigned effective June 30, 2025, and simultaneously entered into a Fifth Amendment to his employment agreement to remain as Chief Architect, a non-executive individual-contributor role.
- Base salary: unchanged at $550,000 for 2025.
- Cash incentive bonus: 100 % of salary for 1H25 and 70 % for 2H25, delivering a blended 85 % target, or $467,500, subject to the same corporate metrics used for other senior executives.
- Equity awards: (1) Previously granted RSUs with a $2.75 million grant-date value (50 % of his $5.5 million CTO target opportunity); (2) an additional RSU award valued at $750,000 will be granted 15 July 2025, calculated by dividing $750,000 by the 20-day average share price. All RSUs vest in 16 equal quarterly instalments beginning 15 Aug 2025, contingent upon continued service.
The amendment is filed as Exhibit 10.1.
Item 7.01 – Regulation FD. The company furnished a press release (Exhibit 99.1) announcing the appointment of Amy Yeh as the new Chief Technology Officer. The information under Item 7.01 is considered “furnished,” not “filed,” under the Exchange Act.
FAQ
What is the current stock price of Palatin Tech (PTN)?
What is the market cap of Palatin Tech (PTN)?
What is the core focus of Palatin Technologies?
Which therapeutic areas does Palatin address?
How does Palatin Technologies generate its revenue?
What makes the company’s approach unique?
How does Palatin ensure the credibility of its scientific data?
What role does collaboration play in Palatin’s strategy?
How is Palatin Technologies positioned within the competitive biopharmaceutical landscape?
